Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Spero Therapeutics Inc (SPRO – Research Report) yesterday and set a price target of $27. The company’s shares closed yesterday at $7.68, close to its 52-week low of $5.52.
“We rate SPRO Overweight. As the company advances its pipeline toward commercialization, we expect upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations to drive SPRO’s stock higher. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our $27 12-month price target. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our $27 12-month price target.”
According to TipRanks.com, Chen is a 3-star analyst with an average return of 2.3% and a 33.4% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
Currently, the analyst consensus on Spero Therapeutics Inc is a Moderate Buy with an average price target of $22.
The company has a one-year high of $19 and a one-year low of $5.52. Currently, Spero Therapeutics Inc has an average volume of 80.52K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206.